Lexicon Pharmaceuticals | LXRX - Interest Expense On Debt


Lexicon Pharmaceuticals reported $2.03M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Abbott USD 68M 26M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Akebia Therapeutics 362.52M 357.69M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Illumina USD 26M 1000K Dec/2025
Insmed USD 20.08M 517K Mar/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
MannKind USD 12.43M 1.44M Mar/2026
Merck USD 479M 67M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Novartis USD 343M 39M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Thermo Fisher Scientific USD 354M 11M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
United Therapeutics USD 3.1M 100K Dec/2025
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025